Kala Pharmaceuticals Inc Receives a Buy from Wedbush


Wedbush analyst Liana Moussatos reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA) today and set a price target of $47. The company’s shares opened today at $17.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.8% and a 44.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

Kala Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $46.

See today’s analyst top recommended stocks >>

The company has a one-year high of $26.75 and a one-year low of $11.81. Currently, Kala Pharmaceuticals Inc has an average volume of 174K.

Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts